Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine.
Streptococcus pneumoniae is a major respiratory pathogen of infants, children, and the elderly. Polysaccharide vaccines have been useful in adult populations but do not elicit protective immunity in infants and young children. To enhance their immunogenicity, vaccines of pneumococcal polysaccharides conjugated to proteins are being developed. In this study antibody levels and opsonic activities were compared in sera of infants and adults injected with pneumococcal polysaccharide type 6B (Pn6B) conjugated to tetanus toxoid (TT) (Pn6B-TT). Healthy infants were injected with Pn6B-TT; group A was injected at 3, 4, and 6 months of age, and group B was injected at 7 and 9 months of age. A booster injection was given at 18 months. Adults were injected once. Antibodies were measured by enzyme-linked immunosorbent assay and radioimmunoassay, and their functional activities were measured by opsonophagocytosis of radiolabelled pneumococci. In adults, increases in immunoglobulin M (IgM), IgG, IgA, IgG1, and IgG2 to Pn6B were observed. Infants reached adult levels of IgG1 anti-Pn6B after the primary injections. After the booster injection the infant groups had total IgG- and IgM-Pn6B antibody levels similar to those of adults. After the booster injection, IgG1 was the dominant infant anti-Pn6B isotype and at a level higher than in vaccinated adults, but IgA and IgG2 antibodies remained at very low levels. Opsonic activity increased significantly after Pn6B-TT injections; the highest infant sera showed opsonic activity comparable to that of vaccinated adults. Overall, opsonic activity correlated best with total and IgG anti-Pn6B antibodies (r = 0.741, r = 0.653, respectively; n = 35) and was highest in sera with high levels of all Pn6B antibody isotypes. The results indicate the protective potential of a pneumococcal 6B polysaccharide protein conjugate vaccine for young infants.
Vidarsson
G
G
Departments of Immunology, Reykjavik, Iceland.
Sigurdardottir
S T
ST
Gudnason
T
T
Kjartansson
S
S
Kristinsson
K G
KG
Ingolfsdottir
G
G
Jonsson
S
S
Valdimarsson
H
H
Schiffman
G
G
Schneerson
R
R
Jonsdottir
I
I
D000328:Adult; D000367:Age Factors; D000907:Antibodies, Bacterial / Q000097:blood*; D001428:Bacterial Vaccines / Q000276:immunology*; D002675:Child, Preschool; D005069:Evaluation Studies as Topic; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D009895:Opsonin Proteins / Q000097:blood; D010587:Phagocytosis; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000276:immunology*; D013745:Tetanus Toxoid / Q000276:immunology; D014611:Vaccination
D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D018796:Immunoconjugates; D007074:Immunoglobulin G; D009895:Opsonin Proteins; D011135:Polysaccharides, Bacterial; D013745:Tetanus Toxoid